Feedback

Pfizer increases mark of efficacy of its vaccine up to 94%

Source : 112 Ukraine

170 cases of infection with Covid-19 among the members of the testing were observed during the trials
19:00, 18 November 2020

Reuters

During the final stage of the trial of the vaccine against coronavirus infection developed by Pfizer and BioNTech, its efficacy was increased up to 94% as Pfizer reported.

According to the company, 170 cases of infection with Covid-19 among the members of the testing were observed during the trials. However, 162 cases were observed among the representatives of the control group who received the placebo, not the vaccine. Only eight people got infected among those who received a real vaccine.

Related: Kazakhstan to produce Russian vaccine against Covid-19

The company also noted that the vaccine showed high efficiency in all groups – regardless of age, gender, or race of people. Particularly, the efficacy of the vaccine for people over 65-year-old made 94%. Meanwhile, the elder people got through vaccination easier and complained about side effects less often.

It is noted that it is planned to submit the vaccine for approval of the regulating bodies of the U.S.

Related: Vaccine against Covid-19 not to stop pandemic, - WHO

As we reported earlier, according to the results of the clinical trials, Moderna's vaccine against coronavirus is 94.5% effective. The trial involved 30,000 people in the US with half being given two doses of the vaccine, four weeks apart. The rest had dummy injections.

 

 

Topics:
Система Orphus

If you find an error, highlight the desired text and press Ctrl + Enter, to tell about it

Comments
see more